Analyst Ritu Baral from TD Cowen maintained a Hold rating on Sarepta Therapeutics and keeping the price target at $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Hold rating due to a combination of factors impacting Sarepta Therapeutics. The company’s recent financial performance showed a decrease in Elevidys revenue by 25% quarter-over-quarter, although it was in line with preannounced figures. This decline, alongside the ongoing discussions with the FDA regarding safety labeling and risk mitigation for non-ambulatory patients, contributes to the cautious outlook.
Additionally, while the company has resumed Elevidys shipments for ambulatory patients, there are expected delays for many patients due to insurance reverifications and reauthorizations. These operational challenges, coupled with the importance of upcoming clinical data in the second half of 2025 for future valuation, suggest a balanced risk-reward scenario, justifying the Hold rating.
In another report released today, Goldman Sachs also maintained a Hold rating on the stock with a $19.00 price target.